NASDAQ$INBX
Inhibrx Biosciences Inc · Q4 2026 earnings
Q4 2026 earnings · · After market close · Investor relations
Briefing
Inhibrx Biosciences Inc reported a net loss of $33.4 million for the first quarter ended March 31, 2026.
Inhibrx Biosciences Inc, a clinical-stage biopharmaceutical company, reported operating expenses of $30.9 million for the quarter, driven by research and development activities. The company maintained a strong cash position of $161.7 million while advancing its pipeline of biologic therapeutic candidates. Net loss per share was $2.15 on a basic and diluted basis.
- Net loss for Q1 2026 was $33.4 million compared to $43.3 million in Q1 2025.
- Research and development expenses decreased to $25.2 million from $36.9 million year-over-year.
- Cash and cash equivalents increased to $161.7 million following $75 million debt financing.
- Company remains focused on advancing ozekibart and INBRX-106 clinical programs with no revenue generated.
Headline financials
Revenue & EPS history
Inhibrx Biosciences Inc · Revenue · Quarterly
$0
Forward guidance
Company plans to meet with FDA in second half of 2026 regarding regulatory pathways for ozekibart and initiate Phase 3 for INBRX-106.
Tailwinds
- Positive interim data from colorectal cancer and Ewing sarcoma trials
- Statistically significant PFS benefit in chondrosarcoma trial
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports · overlaid with Q4 2026
-2.2%
Avg return
Earnings day
-0.4%
Avg return
5 days after
+1.4%
Avg return
30 days after
36%
8 / 22 earnings
Positive
+8.4%
Q2 2021
Best reaction
-17.4%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.2% | -13.9% | -33.7% | |
| Q3 2025 | +5.7% | +10.1% | +6.6% | |
| Q2 2025 | +1.9% | -2.4% | +16.8% | |
| Q1 2025 | -1.9% | -1.3% | +9.9% | |
| Q4 2024 | -0.7% | +1.8% | -18.7% | |
| Q3 2024 | -10.5% | -7.5% | -5.4% | |
| Q2 2024 | +0.4% | +10.8% | +34.0% | |
| Q1 2024 | -0.4% | — | — | |
| Q4 2023 | -7.4% | — | — | |
| Q3 2023 | +0.1% | — | — | |
| Q2 2023 | -17.4% | — | — | |
| Q1 2023 | -2.5% | — | — | |
| Q4 2022 | -0.8% | — | — | |
| Q3 2022 | -4.2% | — | — | |
| Q2 2022 | +7.4% | — | — | |
| Q1 2022 | -7.1% | — | — | |
| Q4 2021 | -1.6% | — | — | |
| Q3 2021 | -3.5% | — | — | |
| Q2 2021 | +8.4% | — | — | |
| Q1 2021 | +3.7% | — | — | |
| Q4 2020 | -13.6% | — | — | |
| Q3 2020 | -4.5% | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro